MEDANTA.NS(MEDANTA.NS)
MEDANTA.NS
No analyst ratings available
No analyst price targets available for MEDANTA.NS
Analyst coverage may not be available for this symbol
No recent analyst actions
| Metric | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|
| Revenue Avg | $51.97B | $59.78B | $69.47B | $80.99B |
| Low | $49.33B | $54.95B | $65.22B | $76.05B |
| High | $56.15B | $63.21B | $74.21B | $85.50B |
| EBITDA Avg | $12.13B | $13.95B | $16.21B | $18.90B |
| Low | $11.51B | $12.82B | $15.22B | $17.74B |
| High | $13.10B | $14.75B | $17.32B | $19.95B |
| EBIT Avg | $10.05B | $11.56B | $13.43B | $15.66B |
| Low | $9.54B | $10.63B | $12.61B | $14.71B |
| High | $10.86B | $12.22B | $14.35B | $16.53B |
| Net Income Avg | $7.04B | $8.66B | $9.93B | $9.64B |
| Low | $6.15B | $7.69B | $8.94B | $8.88B |
| High | $7.57B | $9.62B | $10.43B | $10.34B |
| EPS Avg | $25.77 | $32.11 | $36.89 | $35.81 |
| Low | $22.82 | $28.56 | $33.19 | $32.97 |
| High | $28.10 | $35.72 | $38.71 | $38.40 |
| Analysts (Rev / EPS) | 13 / 13 | 17 / 15 | 7 / 5 | 3 / 1 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 |
|---|---|---|---|
| Revenue Avg | $12.11B | $12.56B | $12.73B |
| Low | $12.11B | $12.56B | $12.73B |
| High | $12.11B | $12.56B | $12.73B |
| EBITDA Avg | $2.83B | $2.93B | $2.97B |
| Low | $2.83B | $2.93B | $2.97B |
| High | $2.83B | $2.93B | $2.97B |
| EBIT Avg | $2.34B | $2.43B | $2.46B |
| Low | $2.34B | $2.43B | $2.46B |
| High | $2.34B | $2.43B | $2.46B |
| Net Income Avg | — | — | — |
| Low | — | — | — |
| High | — | — | — |
| EPS Avg | — | — | — |
| Low | — | — | — |
| High | — | — | — |
| Analysts (Rev / EPS) | 1 / 3 | 1 / 3 | 1 / 3 |